Payment overview · 2025
General Payments
$1,207.41
61 reported records · 22 companies
Healthcare provider profile · identity verified
David M Cantrell, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MARIETTA, GA · NPI 1467425124
Verified facts
What the public records show
CMS Open Payments records show David M Cantrell, MD received $1,207.41 in general payments during 2025 across 61 reported records.
Novo Nordisk Inc accounted for 15.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Jardiance, Mounjaro, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 222 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Soliqua 100-33 by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $181.83 | 15.1% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $135.06 | 11.2% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $132.10 | 10.9% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $108.28 | 9.0% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $98.72 | 8.2% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $73.41 | 6.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.70 | 5.3% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $49.53 | 4.1% | 2 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $48.69 | 4.0% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $36.69 | 3.0% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $33.78 | 2.8% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $32.60 | 2.7% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.28 | 2.7% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $26.49 | 2.2% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.64 | 1.9% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $19.93 | 1.6% | 1 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $19.89 | 1.6% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.88 | 1.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.34 | 1.6% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $19.18 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.49 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.90 | 1.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,207.41 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $181.83 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $132.10 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $110.60 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $98.72 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $91.82 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $73.41 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $49.53 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $49.53 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $49.53 | 3 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $48.69 | 2 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $48.69 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.00 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.00 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.00 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $43.78 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $43.24 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $43.24 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $36.69 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $33.78 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $32.60 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $32.28 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $28.49 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.64 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $19.93 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.88 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.34 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $19.18 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAMAX Normalized: vyndamax |
Drug | PFIZER INC. | $18.67 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $14.17 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $12.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 33 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 60 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
222 | 59 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
60 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
136 | 34 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 872 | 274 |
| Lisinopril | Lisinopril | 507 | 161 |
| Amlodipine Besylate | Amlodipine Besylate | 418 | 145 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 107 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 346 | 116 |
| Pantoprazole Sodium | Pantoprazole Sodium | 261 | 86 |
| Metformin Hcl Er | Metformin Hcl | 254 | 83 |
| Omeprazole | Omeprazole | 251 | 88 |
| Synthroid | Levothyroxine Sodium | 222 | 59 |
| Gabapentin | Gabapentin | 214 | 73 |
| Losartan Potassium | Losartan Potassium | 192 | 58 |
| Metoprolol Succinate | Metoprolol Succinate | 175 | 53 |
| Ezetimibe | Ezetimibe | 168 | 56 |
| Carvedilol | Carvedilol | 164 | 60 |
| Simvastatin | Simvastatin | 161 | 48 |
| Famotidine | Famotidine | 159 | 45 |
| Furosemide | Furosemide | 159 | 61 |
| Farxiga | Dapagliflozin Propanediol | 152 | 38 |
| Irbesartan | Irbesartan | 142 | 46 |
| Metformin Hcl | Metformin Hcl | 142 | 49 |
| Hydrochlorothiazide | Hydrochlorothiazide | 140 | 48 |
| Eliquis | Apixaban | 136 | 34 |
| Valsartan | Valsartan | 132 | 42 |
| Trazodone Hcl | Trazodone Hcl | 130 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 126 | 43 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 40 |
| Alprazolam | Alprazolam | 118 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 38 |
| Potassium Chloride | Potassium Chloride | 114 | 33 |
| Meloxicam | Meloxicam | 112 | 44 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 111 | 31 |
| Allopurinol | Allopurinol | 100 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 100 | 32 |
| Sertraline Hcl | Sertraline Hcl | 88 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 31 |
| Citalopram Hbr | Citalopram Hydrobromide | 83 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 83 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 83 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 22 |
| Tramadol Hcl | Tramadol Hcl | 68 | 22 |
| Temazepam | Temazepam | 67 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 65 | 23 |
| Lovastatin | Lovastatin | 65 | 21 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 61 | 13 |
| Ozempic | Semaglutide | 60 | 13 |
| Telmisartan | Telmisartan | 59 | 15 |
| Bupropion Xl | Bupropion Hcl | 58 | 22 |
| Mounjaro | Tirzepatide | 55 | suppressed |
| Vascepa | Icosapent Ethyl | 53 | suppressed |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 51 | 19 |
| Celecoxib | Celecoxib | 50 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 46 | 13 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 40 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | 16 |
| Prednisone | Prednisone | 38 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 37 | 19 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 13 |
| Clonazepam | Clonazepam | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | 11 |
| Spironolactone | Spironolactone | 33 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 32 | suppressed |
| Sucralfate | Sucralfate | 32 | suppressed |
| Trulicity | Dulaglutide | 32 | suppressed |
| Ramipril | Ramipril | 31 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | 13 |
| Lorazepam | Lorazepam | 29 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 25 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 24 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | 11 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Gemtesa | Vibegron | 22 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 22 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | 13 |
| Pregabalin | Pregabalin | 22 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 22 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 21 | 11 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 12 |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 18 |
| Praluent Pen | Alirocumab | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydrocortisone | Hydrocortisone | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 16 | suppressed |
| Testosterone | Testosterone | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Ondansetron Odt | Ondansetron | 15 | suppressed |
| Teriparatide | Teriparatide | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Klor-Con M10 | Potassium Chloride | 13 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,207.41 · 61 records | Novo Nordisk Inc | ABRYSVO, AREXVY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, FREESTYLE LIBRE 3, GEMTESA, General - Pain Management, JARDIANCE, Kerendia, LEQEMBI, LEQVIO, MOUNJARO, NEXLETOL, OTEZLA, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REPATHA, Rybelsus, SHINGRIX, TZIELD, UBRELVY, VOQUEZNA, VYNDAMAX, VYNDAQEL, Veozah, XIFAXAN, ZEPBOUND | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error